Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: Are all family members bad players?

Cyclooxygenase-2 (COX-2) inhibitors dilemna in cardiovascular medicine has not been resolved yet. The cardiovascular safety of selective COX-2 inhibitors other than rofecoxib is uncertain. Given the ongoing controversy surrounding the use of COX-2 inhibitors, futher clinical studies with different types of drugs are required to establish safety and therapeutic benefit in patients with coronary artery disease.